Cellceutix, now known as Innovation Pharma, is focused on developing innovative medical therapies, particularly through its lead drug candidate, Brilacidin. This compound is a small molecule mimetic of defensins, which are naturally occurring antimicrobial peptides that play a crucial role in the body's immune response. Brilacidin exhibits broad-spectrum antimicrobial properties and has been recognized for its potential to treat various conditions, including oral mucositis, a painful side effect of chemoradiation therapy. The drug has undergone extensive clinical evaluation, with over 500 patients treated, and has received Fast Track designation from the FDA, highlighting its significance in addressing infectious diseases and inflammation.

In addition to Brilacidin, Innovation Pharma is developing a novel image-guided surgical laser platform known as BEAMED, aimed at treating cancer and epilepsy. This technology represents the company's commitment to advancing medical treatments through innovative approaches. The company, established in 2007 and based in Wakefield, Massachusetts, is actively exploring additional investment opportunities to enhance its portfolio and further its mission of delivering effective therapies for various health challenges.

United States

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Please visit Cellceutix's web site at www.cellceutix.com.

Cellceutix

Company Details